Inventiva appoints Chris Benecchi as COO ahead of MASH Phase 3 readout
Inventiva has appointed Chris Benecchi as Chief Operating Officer, bringing in a seasoned biopharmaceutical executive to steer the company through what may be its most consequential period to date. The hire comes as the dual-listed company braces for topline data from its NATiV3 pivotal Phase 3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, now expected in the fourth quarter of 2026.
Benecchi joins from Motric Bio, an Aditum Bio company where he served as chief executive. Before that, he held three senior roles at Sage Therapeutics including chief operating officer, chief business officer, and chief commercial officer, and was centrally involved in the US launch of ZURZUVAE. Earlier experience includes global launch readiness for UCB's bimekizumab and commercial leadership across Alexion's rare-disease portfolio, as well as positions at Acorda Therapeutics, Takeda Pharmaceuticals, and Johnson and Johnson. He holds an MBA from Duke University's Fuqua School of Business.
Commercial build-out
Inventiva's chief executive Andrew Obenshain said Benecchi's background in "competitive and access-challenged markets" is well matched to the MASH opportunity. The company is targeting a potential US launch of lanifibranor in 2028, subject to regulatory approval, and has described itself as actively building the organisational infrastructure and commercial capabilities to support that timeline.
Benecchi said he is joining "with a clear mandate to build the organisation and capabilities needed to prepare for the potential launch of lanifibranor." Both executives were careful to condition their statements on regulatory approval, reflecting the fact that lanifibranor remains an investigational medicine with no marketing authorisation in any jurisdiction.
Lanifibranor is a pan-PPAR agonist administered orally. The NATiV3 trial is evaluating it in adults with MASH, a progressive chronic liver disease previously known as non-alcoholic steatohepatitis. The company notes in its filing disclosures that a Suspected Unexpected Serious Adverse Reaction was previously reported in the trial, and that this could affect results or timing, though the independent data monitoring committee has continued the study.
Market context
MASH has become one of the most watched therapeutic areas in hepatology, with analysts projecting a multi-billion-dollar addressable market as prevalence rises alongside global rates of obesity and type 2 diabetes. Madrigal Pharmaceuticals obtained FDA approval for resmetirom, marketed as Rezdiffra, in March 2024, making it the first approved pharmacological treatment for MASH with liver fibrosis. That approval set a regulatory benchmark and created a commercial comparator that lanifibranor will need to address clearly if it reaches the market.
Other companies including Akero Therapeutics and 89bio are advancing late-stage candidates in the same space, meaning Inventiva would enter a market that is no longer empty but not yet crowded. The differentiation argument for lanifibranor, as a pan-PPAR agonist with a distinct mechanism from resmetirom's thyroid hormone receptor beta agonism, will be tested both by the NATiV3 data and by payer discussions that typically begin well before an NDA filing.
Inventiva's decision to appoint a COO at this stage, rather than waiting for a readout, signals confidence in the programme and reflects a broader industry pattern in which clinical-stage companies front-load commercial infrastructure to avoid losing ground in the post-approval window. Whether the Q4 2026 data can support that investment will become clear within months.